Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Netilmicin→

Netilmicin PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
56391-56-1
Molecular formula
C21H41N5O7
Molecular weight
475.6 g/mol
Drug class
Aminoglycoside antibacterial30S ribosomal subunit inhibitor
Mechanism of action
Binds the 30S ribosomal subunit, interfering with initiation and causing misreading of mRNA, which leads to production of abnormal proteins and bactericidal activity against susceptible aerobic bacteria.
Indications / reported uses
  • Treatment of serious infections caused by susceptible Gram-negative aerobic bacteria with parenteral formulations where authorised
  • Topical ophthalmic or otic formulations are used for selected superficial bacterial infections of the eye or ear; route-specific products and indications are not interchangeable

Sources: NLM MeSH — Netilmicin · PubMed — Netilmicin antibacterial pharmacology · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Aminoglycoside antibacterial; 30S ribosomal subunit inhibitor

Mechanism of action

Binds the 30S ribosomal subunit, interfering with initiation and causing misreading of mRNA, which leads to production of abnormal proteins and bactericidal activity against susceptible aerobic bacteria.

General use cases

  • Treatment of serious infections caused by susceptible Gram-negative aerobic bacteria with parenteral formulations where authorised
  • Topical ophthalmic or otic formulations are used for selected superficial bacterial infections of the eye or ear; route-specific products and indications are not interchangeable

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Netilmicin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Netilmicin Permitted Daily Exposure (PDE) report (the Netilmicin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Netilmicin Occupational Exposure Limit (OEL) report (the Netilmicin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.